Full Breakdown
Intellia’s In-Vivo CRISPR Therapy Cuts Hereditary Angioedema Attacks in Phase 3 Trial
4/28/2026, 1:12:16 AM
Phase 3 Trial Shows In-Vivo CRISPR Success
Intellia Therapeutics reported that a 50 mg infusion of lonvoguran ziclumeran (lonvo-z) reduced hereditary angioedema (HAE), a rare disease affecting 1 in 50,000 people, attacks by 87% versus placebo in a Phase 3 trial of 80 patients (52 treated, 28 placebo). Attack-free and therapy-free rates were 62% versus 11% for placebo. No serious adverse events occurred; infusion-related reactions, headache, and fatigue were common. Lonvo-z uses CRISPR/Cas9 to inactivate the KLKB1 gene, lowering kallikrein and bradykinin, a paradigm shift for HAE treatment.
Official Statements
Intellia said the trial met its secondary endpoints, described safety as “favorable,” and began a rolling orphan-drug BLA with FDA, targeting filing in H2 2026 and U.S. launch in H1 2027.
Criticism & Opposition
Analysts cite BioMarin’s withdrawal of a hemophilia-A gene therapy after weak sales. Intellia trial reported a patient death from liver toxicity. John Leonard cautioned that durability beyond six months remains unproven.
Next Steps
Data will be presented at the EAACI Congress in Istanbul (June 12-15 2026). The rolling BLA is slated for completion in late 2026, followed by FDA review and a U.S. launch in 2027, regulatory approval.
Verbatim Quotes
- “When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we've had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you're actually changing a gene that causes disease,” — John Leonard, CEO, Intellia Therapeutics.
- “And, as far as we can tell, we don't have a single patient in this program or other program where there's been any waning of the effect of what we did to the gene or the effect of what we've seen with the clinical aspects of the disease itself.” — John Leonard, CEO, Intellia Therapeutics.
- “As the first Phase 3 data reported for an in vivo gene editing therapy, today’s HAELO results represent a profound milestone for Intellia, the broader CRISPR and precision medicine fields and, most importantly, the HAE community,” — John Leonard, M.D., President and CEO, Intellia Therapeutics.
- “Despite the availability of several HAE treatments, many patients continue to experience significant burdens related to the disease, including breakthrough attacks and challenges associated with chronic treatment,” — Aleena Banerji, M.D., Harvard Medical School professor and HAELO principal investigator.
